Tempest Therapeutics, Inc. (TPST) · Oct 20, 2026 · Rights change
Meeting adjourned — 74.3% represented; 75% approval threshold
Tempest’s special meeting was adjourned again after failing to secure enough votes for its charter amendment, pushing the decision to November 12.
Tempest is a clinical-stage biotech shifting toward next-generation in vivo CAR-T therapies while using partnerships and external funding to advance its pipeline efficiently. This filing is about governance execution, not a new clinical or financing milestone.
The charter amendment still lacks enough support. Only 74.3% of shares were represented, below the proposal’s requirement for approval by holders of at least 75% of all eligible votes. 〔0〕 〔1〕
This is a delay, not a defeat—but it is another execution setback. The company adjourned because it did not have sufficient votes, after earlier adjournments in July, August, and September. 〔2〕 The direction was already known from the repeated postponements, so the new information is mainly that management still has not closed the gap.
The immediate business impact is limited. Allowing written consent and replacing specified supermajority provisions could make future corporate actions easier, but the filing does not change Tempest’s CAR-T programs, funding arrangements, or clinical timelines. The meeting will reconvene on November 12, 2026. 〔3〕
Bottom line: Tempest has bought more time but still cannot secure approval for a governance change it has been pursuing for months. It complicates execution modestly, while leaving the underlying drug-development story unchanged.
Reconvened special meeting, November 12, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!